IRIS Accounts Production v24.3.2.46 10701147 Board of Directors Board of Directors 1.4.23 31.3.24 31.3.24 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh107011472023-03-31107011472024-03-31107011472023-04-012024-03-31107011472022-03-31107011472022-04-012023-03-31107011472023-03-3110701147ns15:EnglandWales2023-04-012024-03-3110701147ns14:PoundSterling2023-04-012024-03-3110701147ns10:Director12023-04-012024-03-3110701147ns10:Director22023-04-012024-03-3110701147ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3110701147ns10:SmallEntities2023-04-012024-03-3110701147ns10:AuditExemptWithAccountantsReport2023-04-012024-03-3110701147ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-03-3110701147ns10:SmallCompaniesRegimeForAccounts2023-04-012024-03-3110701147ns10:FullAccounts2023-04-012024-03-311070114712023-04-012024-03-3110701147ns10:RegisteredOffice2023-04-012024-03-3110701147ns5:CurrentFinancialInstruments2024-03-3110701147ns5:CurrentFinancialInstruments2023-03-3110701147ns5:ShareCapital2024-03-3110701147ns5:ShareCapital2023-03-3110701147ns5:RetainedEarningsAccumulatedLosses2024-03-3110701147ns5:RetainedEarningsAccumulatedLosses2023-03-3110701147ns5:NetGoodwill2023-04-012024-03-3110701147ns5:IntangibleAssetsOtherThanGoodwill2023-04-012024-03-3110701147ns5:FurnitureFittings2023-04-012024-03-3110701147ns5:MotorVehicles2023-04-012024-03-3110701147ns5:NetGoodwill2023-03-3110701147ns5:NetGoodwill2024-03-3110701147ns5:NetGoodwill2023-03-3110701147ns5:FurnitureFittings2023-03-3110701147ns5:MotorVehicles2023-03-3110701147ns5:FurnitureFittings2024-03-3110701147ns5:MotorVehicles2024-03-3110701147ns5:FurnitureFittings2023-03-3110701147ns5:MotorVehicles2023-03-3110701147ns5:CostValuation2023-03-3110701147ns5:AdditionsToInvestments2024-03-3110701147ns5:RevaluationsIncreaseDecreaseInInvestments2024-03-3110701147ns5:CostValuation2024-03-3110701147ns5:WithinOneYearns5:CurrentFinancialInstruments2024-03-3110701147ns5:WithinOneYearns5:CurrentFinancialInstruments2023-03-31
REGISTERED NUMBER: 10701147 (England and Wales)













UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024

FOR

RIYAZ SHAH ONCOLOGY LTD

RIYAZ SHAH ONCOLOGY LTD (REGISTERED NUMBER: 10701147)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4

Chartered Certified Accountants' Report 7

RIYAZ SHAH ONCOLOGY LTD

COMPANY INFORMATION
FOR THE YEAR ENDED 31 MARCH 2024







DIRECTORS: Dr R N H Shah
Mrs R Ishtiaq





REGISTERED OFFICE: Lonsdale House
High Street
Lutterworth
Leicestershire
LE17 4AD





REGISTERED NUMBER: 10701147 (England and Wales)





ACCOUNTANTS: Crowfoot & Co Accountants Ltd
Lonsdale House
High Street
Lutterworth
Leicestershire
LE17 4AD

RIYAZ SHAH ONCOLOGY LTD (REGISTERED NUMBER: 10701147)

BALANCE SHEET
31 MARCH 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 - -
Tangible assets 5 104,503 26,983
Investments 6 153,136 127,566
257,639 154,549

CURRENT ASSETS
Debtors 7 11,950 25,805
Cash at bank 158,573 182,304
170,523 208,109
CREDITORS
Amounts falling due within one year 8 6,968 26,029
NET CURRENT ASSETS 163,555 182,080
TOTAL ASSETS LESS CURRENT
LIABILITIES

421,194

336,629

PROVISIONS FOR LIABILITIES 19,856 5,306
NET ASSETS 401,338 331,323

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 401,238 331,223
SHAREHOLDERS' FUNDS 401,338 331,323

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

RIYAZ SHAH ONCOLOGY LTD (REGISTERED NUMBER: 10701147)

BALANCE SHEET - continued
31 MARCH 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 24 December 2024 and were signed on its behalf by:




Dr R N H Shah - Director



Mrs R Ishtiaq - Director


RIYAZ SHAH ONCOLOGY LTD (REGISTERED NUMBER: 10701147)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

1. STATUTORY INFORMATION

Riyaz Shah Oncology Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2017, is being amortised evenly over its estimated useful life of five years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Equipment - 15% on reducing balance
Motor vehicles - 25% on reducing balance

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

RIYAZ SHAH ONCOLOGY LTD (REGISTERED NUMBER: 10701147)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2023 - 1 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 April 2023
and 31 March 2024 10,000
AMORTISATION
At 1 April 2023
and 31 March 2024 10,000
NET BOOK VALUE
At 31 March 2024 -
At 31 March 2023 -

5. TANGIBLE FIXED ASSETS
Motor
Equipment vehicles Totals
£    £    £   
COST
At 1 April 2023 14,492 70,005 84,497
Additions 1,024 111,900 112,924
At 31 March 2024 15,516 181,905 197,421
DEPRECIATION
At 1 April 2023 10,183 47,331 57,514
Charge for year 1,760 33,644 35,404
At 31 March 2024 11,943 80,975 92,918
NET BOOK VALUE
At 31 March 2024 3,573 100,930 104,503
At 31 March 2023 4,309 22,674 26,983

6. FIXED ASSET INVESTMENTS
Other
investments
£   
COST OR VALUATION
At 1 April 2023 127,566
Additions 9,621
Revaluations 15,949
At 31 March 2024 153,136
NET BOOK VALUE
At 31 March 2024 153,136
At 31 March 2023 127,566

RIYAZ SHAH ONCOLOGY LTD (REGISTERED NUMBER: 10701147)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024

6. FIXED ASSET INVESTMENTS - continued

Cost or valuation at 31 March 2024 is represented by:

Other
investments
£   
Valuation in 2024 153,136

7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 11,950 25,805

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Taxation and social security 1,652 19,540
Other creditors 5,316 6,489
6,968 26,029

9. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

At 31 March 2024, an amount of £4,236 (2023 £5,529) was due to the directors' which amount is included within creditors on the balance sheet.

CHARTERED CERTIFIED ACCOUNTANTS' REPORT TO THE BOARD OF DIRECTORS
ON THE UNAUDITED FINANCIAL STATEMENTS OF
RIYAZ SHAH ONCOLOGY LTD

The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Directors are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Riyaz Shah Oncology Ltd for the year ended 31 March 2024 which comprise the Income Statement, Balance Sheet, Statement of Changes in Equity and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at http://www.accaglobal.com/rulebook.

This report is made solely to the Board of Directors of Riyaz Shah Oncology Ltd, as a body, in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Riyaz Shah Oncology Ltd and state those matters that we have agreed to state to the Board of Directors of Riyaz Shah Oncology Ltd, as a body, in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at http://www.accaglobal.com/factsheet163. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and its Board of Directors, as a body, for our work or for this report.

It is your duty to ensure that Riyaz Shah Oncology Ltd has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Riyaz Shah Oncology Ltd. You consider that Riyaz Shah Oncology Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Riyaz Shah Oncology Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.






Crowfoot & Co Accountants Ltd
Lonsdale House
High Street
Lutterworth
Leicestershire
LE17 4AD


24 December 2024